Brean Capital analyst Difei Yang reiterated a Buy rating and boosted his price target on Aerie Pharma (NASDAQ: AERI) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Momentum Movers

Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data September 17, 2015 10:09 AM RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 DataSeptember 17, 2015 9:00 AM Aerie Pharma (AERI) PT Raised to $40 at Cantor FitzgeraldSeptember 17, 2015 7:24 AM Aerie Pharma (AERI) PT Raised to $45 at Needham & CompanySeptember 17, 2015 6:22 AM Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy EndpointSeptember 16, 2015 4:04 PM Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy ResultsSeptember 16, 2015 4:01 PM